Supplementary Materials

Supplementary Material for:

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

Donald M. O'Rourke, MacLean P. Nasrallah, Arati Desai, Jan J. Melenhorst, Keith Mansfield, Jennifer J. D. Morrissette, Maria Martinez-Lage, Steven Brem, Eileen Maloney, Angela Shen, Randi Isaacs, Suyash Mohan, Gabriela Plesa, Simon F. Lacey, Jean-Marc Navenot, Zhaohui Zheng, Bruce L. Levine, Hideho Okada, Carl H. June, Jennifer L. Brogdon, Marcela V. Maus*

*Corresponding author. Email: mvmaus{at}mgh.harvard.edu

Published 19 July 2017, Sci. Transl. Med. 9, eaaa0984 (2017)
DOI: 10.1126/scitranslmed.aaa0984

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Sample stain of peripheral blood T cells for CART-EGFRvIII.
  • Fig. S2. Lack of correlation between engraftment and absolute lymphocyte count.
  • Fig. S3. Histology and CD3 immunohistochemistry stain of pre- and post-CART infusion tumor specimens.
  • Fig. S4. Validation of RNAscope ISH.
  • Fig. S5. Validation of PD-L1 staining.
  • Table S1. Individual patient characteristics.
  • Table S2. Individual product characteristics.
  • Table S3. Individual post-CART infusion events.
  • Table S4. Adverse events at least possibly related to CART-EGFRvIII.
  • Table S5. Immunohistochemical antibodies and ISH probes used.
  • Legend for table S6

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S6. Primary cytokine data (separate Excel file).

[Download Table S6]